The global Lymphoma treatment market is anticipated to grow at a CAGR of around 8% during the forecast period. The Lymphoma treatment industry is gaining traction rapidly with the increasing awareness regarding various therapies available in the market. Since the last decades, there have been a lot of changes in the treatment of lymphoma. Changing from relying on large field high doses of radiation therapy to a combination of chemotherapy and a little bit of some treatment and in some cases just chemotherapy.
Nowadays, most patients who are diagnosed with lymphoma are treated with chemotherapy which can be given by vein or by mouth. There are other patients with lymphoma whose disease is growing slowly and causing so few symptoms that it really can be carefully watched and not treated immediately in contradistinction to the patients with rapidly growing. Lymphomas are oftentimes treated with aggressive high-dose chemotherapy on a very frequent intense schedule to eliminate that lymphoma and cure that patient’s cancer.
A full report of Lymphoma Treatment Market is available at: https://www.omrglobal.com/industry-reports/lymphoma-treatment-market
Additionally, certain lymphomas can benefit from the addition of treatment with radiation and that radiation is generally given by the radiation oncologist following a schedule for a prescribed number of weeks of treatment. The combination of chemotherapy radiation can often be Curative for patients with early-stage lymphoma. However, for patients with advanced lymphoma generally, chemotherapy plus or minus radiation can be given. So, the lymphoma treatment market is significantly affected by the rising use of chemotherapy and a combination of various other therapies.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lymphoma-treatment-market
However, there are some long-term side effects of these potential chemotherapies. For instance, an ABVD (adriamycin bleomycin vinblastine dacarbazine) chemotherapy regimen that is used in the first-line treatment of Hodgkin lymphoma contains many side effects. Adriamycin has some toxiceffects on the heart as it can affect the function of heart muscles and that's why patients get evaluated before starting chemotherapy to make sure that they had good heart function. The bleomycin can cause lung toxicity in some patients.
Other side effects may include a small risk of peripheral neuropathy, affecting the peripheral nerves, causing numbness tingling with some constipation nausea, and vomiting. Although, even with these associated side effects, the adoption of chemotherapy is rising anyway fuelling the lymphoma treatment market during the forecast period.
Few Key Findings in the Report
- Asia-Pacific is expected to be the fastest-growing region in the global lymphoma treatment market during the forecast period.
- North America is estimated to hold significant share in the lymphoma treatment market.
- Chemotherapy is expected to hold the largest by therapy type segment.
Global Lymphoma Treatment Market- Segmentation
By Type
- Hodgkin
- Non-Hodgkin
By Therapy Type
- Radiation therapy
- Chemotherapy
- Others
By Drug Type
- Adcetris
- Rituxan/MabThera
- Imbruvica
- Keytruda
- Revlimid
- Others
Global Lymphoma Treatment Market – Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- AeternaZentaris Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Co.
- Cadila Pharmaceuticals Ltd.
- Celgene Corp.
- Eli Lilly and Co.
- Epizyme, Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404